Anti-BCMA-Anti-CD19-Anti-CD3 Trispecific Molecule

Product Code
AMS.100761-1
$0.00
Order Support
Shipping Information
Product Updates
  • Keep up to date with product offers, resources and news

  • Sign up

The Anti-BCMA-Anti-CD19-Anti-CD3-His Trispecific Antibody is engineered to bind to three different targets simultaneously: 1) BCMA, a B cell antigen that is highly expressed by mature B cells and malignant myeloma cells, 2) CD19, a B-cell marker that is a target for many leukemias and lymphomas, and 3) CD3, a T cell receptor activation signal that leads to cytokine secretion. The multi-functionality of this trispecific antibody allows it to bind to BCMA and CD19 on the tumor cell and CD3 on T cells simultaneously, thus bringing T lymphocytes closer to the cancer cells. The binding event targets the tumor while providing co-stimulatory signals that promote T cell expansion and cytotoxicity against BCMA+ and CD19+ cancer cells.
More Information
SKU AMS.100761-1
Size 50 µg
Species Human
isotype BiTE, variable regions only
Application This product is for research use only. It is not suitable for human diagnostic or therapeutic use. The anti-BCMA-anti CD19-anti-CD3 can be used for studying BCMA+ cancer cell-mediated T cell activation, using either primary T cells or reporter cell lin
Gene synonyms Cluster of Differentiation 19 antibody, B-Lymphocyte Surface Antigen B4 antibody, CVID3 antibody, B-cell maturation antigen antibody, TNFRSF17 antibody, CART antibody, 100761-1, 100761-2
Storage Stable for at least 12 months at -80°C. Avoid freeze/thaw cycles.
Shipping Temp -80°C (dry ice)
Supplier Name BPS Bioscience Inc
For more details visit our Immunotherapy: Bispecific and trispecific antibodies page >For more details visit our CAR-T Cell Research page >